ADVOCATE. CONNECT. INNOVATE.

Bulletin, President's Corner

CLSA’s 2017 California Life Sciences Industry Report Launches this Week & Election Round-Up

RETWritten By:
Sara Radcliffe
President & CEO
CLSA – California Life Sciences Association 


November 24, 2016

Welcoming New Members

Please welcome the 11 new CLSA members who joined us in October:  AbCyte Therapeutics, AcelRx Pharmaceuticals, Inc., Avanir Pharmaceuticals, Beacon Discovery, BioCorRX Pharmaceuticals Inc., Genetech Inc., Modulated Imaging Inc., Optimal Tracers/Northern California PET Imaging Center, Pro-Dex, Protelica, and Telo Therapeutics Inc.!  These great organizations join our robust membership portfolio and add significantly to the expertise and resources available in the CLSA network.

CLSA 2016 Election Round-Up

The 2016 election has drawn to a close, bringing significant changes on several fronts.  I’d like to thank our Federal, State, and Local advocacy teams for their work in creating a comprehensive overview, which you can study here.  I’d also like to recognize the extraordinary efforts that led to the defeat of Proposition 61, the flawed prescription drug contracting measure.  Our team, alongside many of our members, spent countless hours working to defeat this measure, and I’d like to congratulate you on the results of your efforts.

Coming Soon: CLSA’s 2017 California Life Sciences Industry Report

On Nov. 16, CLSA & PwC US will release the 2017 California Life ir2017Sciences Industry Report, our annual report that reveals the employment trends, industry wages, venture capital funding levels, product development, NIH grants and other key data points that characterize California’s life sciences sector.

The 2017 California Life Sciences Industry Report uncovers:

  • New therapies in the development pipeline for California life sciences companies;
  • Number of medical devices approved by the FDA from California medtech companies;
  • Digital health growth, VC data for California companies;
  • Revenue, employment and wage trends for California life sciences companies;
  • Los Angeles Regional Spotlight;
  • Public Policy Outlook; and
  • More

 

Join CLSA Board Member Peter Claude, Partner, PwC, and me for a webinar on Nov. 16, 2016 to discuss the new report, and how life sciences research, development and manufacturing contribute to California’s economy and drive the nationwide life sciences ecosystem.

Click here to register for our complimentary webinar on Nov. 16 at 11 am PT.

 

Pantheon 2016 – There’s Still Time to Celebrate With Us!

pantheon17Join us to celebrate the honorees for the 2016 Pantheon DiNA Awards at CLSA’s largest and most celebrated annual award ceremony. Pantheon recognizes achievements and honors excellence, uniting life sciences leaders in celebration of California’s life sciences sector.  The annual program, now in its 13th year, brings together more than 600 industry pioneers – including founders, investors and educators – and recognizes the achievements and excellence of those at the forefront of innovation in California’s life sciences industry.  Register to honor this year’s winners at the ceremony on Dec. 2 at the Westin St. Francis in San Francisco.

Our 2016 Pantheon Winners Include:

 

 

 

CLSI Expands FAST Accelerator to UC Davis and the Central Valley

sbaWe are proud to report that the California Life Sciences Institute (CLSI) is a recent recipient of the SBA Growth Accelerator Competition, which will allow for expansion of its successful FAST Accelerator to the Central Valley, bringing critical business support to startups coming out of UC Davis.

Click here for more information.

 

CLSI also presented last month to over 250 attendees of the National Investment Banker’s Association conference in Newport Beach, highlighting the exciting investment opportunities in California’s emerging life sciences companies.

 

 

CLSA Announces New Board Members

On Oct. 31, 2016, CLSA added five new members to our board of directors. Senior executives from Actelion Pharmaceuticals, Alexandria Real Estate Equities, Johnson & Johnson Innovation, JLABS, Leerink Partners and Sanofi Genzyme joined the board, adding to the diverse background and expertise of the directing body.

The five new members are Seng Cheng, Global Head of Research, Rare Diseases, Genzyme, a Sanofi Company; Bill Fairey, President, Actelion Pharmaceuticals US; Bryan Giraudo, Managing Director, Investment Banking, Leerink Partners LLC; Stephen Richardson, Chief Operating Officer and Regional Market Director, San Francisco, Alexandria Real Estate Equities, Inc.; and Melinda Richter, Head, Johnson & Johnson Innovation, JLABS. California Life Sciences Association (CLSA), the state’s largest and most influential life sciences advocacy and business leadership organization representing California’s leading life sciences innovators.

Click here to learn more about our new board members.

CLSA Benefits Advantage Trust Savings

CLSA launched our Benefits Advantage Trust earlier this year and found a warm welcome with our member companies – especially those small and midsize companies facing significant increases in their premium cost for 2017.  Companies who entered the CLSA trust found best-in-class, flexible plans and an average 2% decrease (or more) in their overall costs, along with a multi-lingual call center to answer employee benefit questions, health advocates, a benefits administration system, compliance and ACA resources and education and communication assistance.  If your organization is struggling to find the right coverage at the right price, find out if CLSA’s Benefits Advantage Trust can help you control costs, improve compliance, and retain your valuable employees.

 

 

 

 

Be sure to stay connected with us at www.califesciences.org, and follow us @CALifeSciences, Facebook, Instagram, LinkedIn and YouTube.